These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4737112)

  • 21. [Pneumatosis intestinalis in a patient of myasthenia gravis treated with high-dose corticosteroid].
    Kameyama K; Noguchi Y; Matsumoto T; Takenawa H; Fujigasaki H; Kanda T; Mizusawa H
    Rinsho Shinkeigaku; 2003 May; 43(5):277-80. PubMed ID: 12931635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent long-term adrenocorticosteroid treatment of myasthenia gravis.
    Wakata N; Kawamura Y; Kobayashi M; Araki Y; Kinoshita M
    J Neurol; 1991 Feb; 238(1):16-8. PubMed ID: 2030367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit from alternate-day prednisone in myasthenia gravis.
    Warmolts JR; Engel WK
    N Engl J Med; 1972 Jan; 286(1):17-20. PubMed ID: 4331158
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.
    Imai T; Utsugisawa K; Murai H; Tsuda E; Nagane Y; Suzuki Y; Minami N; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Akaishi T; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):513-517. PubMed ID: 29175893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pulmonary volumes and capacities in extremely severe forms of malignant myasthenia under multiyear treatment with alternating doses of prednisolone and artificial pulmonary ventilation].
    Popova LM; Oganesian ShS; Vinitskaia RS
    Anesteziol Reanimatol; 1979; (3):11-6. PubMed ID: 475040
    [No Abstract]   [Full Text] [Related]  

  • 26. [Indicators of central hemodynamics and myocardial contractility function im myasthenic patients on glucocorticoid treatment].
    Mamikonian AA; Gekht BM; Orlov VA
    Klin Med (Mosk); 1990 Apr; 68(4):96-9. PubMed ID: 2370792
    [No Abstract]   [Full Text] [Related]  

  • 27. [The continuous treatment of generalized myasthenia gravis with small doses of prednisolone with or wihtout immunosuppressants (author's transl)].
    Ichikawa Y; Nakata Y; Koriyama K; Komatsuda M; Arimori S
    Nihon Naika Gakkai Zasshi; 1976 Jul; 65(7):669-80. PubMed ID: 988093
    [No Abstract]   [Full Text] [Related]  

  • 28. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients.
    Luther C; Adamopoulou E; Stoeckle C; Brucklacher-Waldert V; Rosenkranz D; Stoltze L; Lauer S; Poeschel S; Melms A; Tolosa E
    J Immunol; 2009 Jul; 183(2):841-8. PubMed ID: 19542375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When the patient fails to respond to treatment: myasthenia gravis.
    Hilton-Jones D
    Pract Neurol; 2007 Nov; 7(6):405-11. PubMed ID: 18024782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
    Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
    Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience with programmed steroid treatment with thymectomy in nonthymomatous myasthenia gravis.
    Endo S; Yamaguchi T; Saito N; Otani S; Hasegawa T; Sato Y; Sohara Y
    Ann Thorac Surg; 2004 May; 77(5):1745-50. PubMed ID: 15111178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Exacerbation of myasthenia gravis by pefloxacin].
    Vial T; Chauplannaz G; Brunel P; Leriche B; Evreux JC
    Rev Neurol (Paris); 1995 Apr; 151(4):286-7. PubMed ID: 7481384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Variants of the pathogenetic therapy of myasthenia gravis].
    Lobzin VS; Poliakova LA; Fedotova TA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(11):1609-14. PubMed ID: 3434054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An unusual presentation of myasthenia gravis.
    Chijoke A; Ogunmodele JA
    West Afr J Med; 2009; 28(6):391-3. PubMed ID: 20486100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
    Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
    J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Myasthenia gravis].
    Tanaka K
    Nihon Rinsho; 2004 May; 62 Suppl 5():580-5. PubMed ID: 15197988
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effect of corticosteroids on the motor end-plate fine structure in experimental autoimmune myasthenia gravis rats and normal rats].
    Satoh A; Tsujihata M; Takashima H; Hazama R; Nagataki S
    Rinsho Shinkeigaku; 1985 Aug; 25(8):990-1000. PubMed ID: 3877587
    [No Abstract]   [Full Text] [Related]  

  • 38. Myasthenia gravis.
    Balakrishnan S; Paul H
    J Indian Med Assoc; 1967 Aug; 49(3):140-2. PubMed ID: 6079093
    [No Abstract]   [Full Text] [Related]  

  • 39. Prolonged neonatal myasthenia gravis: electrophysiological studies.
    Branch CE; Swift TR; Dyken PR
    Ann Neurol; 1978 May; 3(5):416-8. PubMed ID: 727721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation between oral corticosteroid therapy and present disease status in myasthenia gravis].
    Imai T
    Rinsho Shinkeigaku; 2013; 53(11):1306-8. PubMed ID: 24291969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.